No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis

C. Colosimo, C. Pozzilli, M. Frontoni, D. Farina, T. Koudriavtseva, C. Gasperini, M. Salvetti, G. Valesini

Research output: Contribution to journalArticle

Abstract

Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalActa Neurologica Scandinavica
Volume96
Issue number6
Publication statusPublished - 1997

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Autoantibodies
Interferons
Multiple Sclerosis
Serum
Therapeutics
Autoimmunity
Thyroid Gland
DNA

Keywords

  • ANA
  • Anti-cardiolipin
  • Anti-thyroid
  • Interferon β
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis. / Colosimo, C.; Pozzilli, C.; Frontoni, M.; Farina, D.; Koudriavtseva, T.; Gasperini, C.; Salvetti, M.; Valesini, G.

In: Acta Neurologica Scandinavica, Vol. 96, No. 6, 1997, p. 372-374.

Research output: Contribution to journalArticle

Colosimo, C, Pozzilli, C, Frontoni, M, Farina, D, Koudriavtseva, T, Gasperini, C, Salvetti, M & Valesini, G 1997, 'No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis', Acta Neurologica Scandinavica, vol. 96, no. 6, pp. 372-374.
Colosimo, C. ; Pozzilli, C. ; Frontoni, M. ; Farina, D. ; Koudriavtseva, T. ; Gasperini, C. ; Salvetti, M. ; Valesini, G. / No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis. In: Acta Neurologica Scandinavica. 1997 ; Vol. 96, No. 6. pp. 372-374.
@article{cff607ba1b794c5ba1dc2243a3ecf4ec,
title = "No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis",
abstract = "Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29{\%}, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.",
keywords = "ANA, Anti-cardiolipin, Anti-thyroid, Interferon β, Multiple sclerosis",
author = "C. Colosimo and C. Pozzilli and M. Frontoni and D. Farina and T. Koudriavtseva and C. Gasperini and M. Salvetti and G. Valesini",
year = "1997",
language = "English",
volume = "96",
pages = "372--374",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "6",

}

TY - JOUR

T1 - No increase of serum autoantibodies during therapy with recombinant human interferon-β(1a) in relapsing-remitting multiple sclerosis

AU - Colosimo, C.

AU - Pozzilli, C.

AU - Frontoni, M.

AU - Farina, D.

AU - Koudriavtseva, T.

AU - Gasperini, C.

AU - Salvetti, M.

AU - Valesini, G.

PY - 1997

Y1 - 1997

N2 - Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.

AB - Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods - The titres of different autoantibodies were measured in a group of 68 relapsing-remitting MS patients before and during treatment with human recombinant IFN-β(1a) (3 MIU or 9 MIU subcutaneously 3xa week). ANA, anti-thyroid, anticardiolipin serum autoantibodies were assayed in all cases: when patients were found positive to ANA>1: 40, they were also tested for anti-DNA and anti-ENA antibodies. Results - No increase was found in autoantibodies synthesis during 6 months of r-hIFNβ(1a) therapy, either at low or high dosages. The percentage of patients positive to different types of autoantibodies varied between 0 and 29%, which are values similar to those already reported in untreated MS patients. Conclusion - Our data indicate that the short-term use of IFN-β(1a) in MS is safe in terms of the induction of humoral autoimmune responses: however, further follow-up is needed to confirm these findings during long-term treatments.

KW - ANA

KW - Anti-cardiolipin

KW - Anti-thyroid

KW - Interferon β

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0031450321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031450321&partnerID=8YFLogxK

M3 - Article

C2 - 9449474

AN - SCOPUS:0031450321

VL - 96

SP - 372

EP - 374

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 6

ER -